Short-term response to Adalimumab in childhood inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 14, Issue 12, 2008, Pages 1683-1687

  Noe, Joshua D ^a,b   Pfefferkorn, Marian ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Adalimumab; Inflammatory bowel disease; Pediatrics

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; INFLIXIMAB; PREDNISONE; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ANTIBODY PRODUCTION; ARTHRALGIA; ARTICLE; BLURRED VISION; CHILD; CLINICAL ARTICLE; COLON RESECTION; COUGHING; CROHN DISEASE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DUODENUM DISEASE; DYSPNEA; ENTERITIS; ESOPHAGUS DISEASE; FEMALE; FLUSHING; HUMAN; ILEOSTOMY; LICHTIGER COLITIS ACTIVITY INDEX; MALE; MEDICAL RECORD REVIEW; PANIC; PARESTHESIA; PEDIATRIC CROHN DISEASE ACTIVITY INDEX; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; STOMACH DISEASE; TREATMENT DURATION; ULCERATIVE COLITIS; COMPARATIVE STUDY; FOLLOW UP; IMMUNOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 59849102115     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20534     Document Type: Article

References (15)

1. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immun. 1993;94:174-181.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease. Lancet. 2002;359:1541-1549.
3. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology. 2000;119:1148-1157.
4. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
5. Rutgeers P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
6. Jacobstein DA, Markowitz JE, Kirschner BS, et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis. 2005;11:442-446.
7. Miele E, Markowitz JE, Mamula P, et al. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr. 2004;38:502-508.
8. Hanauer SB, Sandborn WJ, Rugeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333.
9. Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239.
10. Colombel JF, Sandborn SJ, Rutgeers P, et al. Adalimumab for the maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
11. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
12. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330: 1841-1845.
13. Peyrin-Biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: an open-label study. Aliment Pharmacol Ther. 2007;25: 675-680.
14. Sandborn WJ, Rutgeers P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829-838.
15. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T-cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265-267.